Siric > Parternships > Industry

A partnership policy with the pharmaceutical industry

Research conducted within Montpellier SIRIC is based on strong partnerships with pharmaceutical companies. This collaboration represents a major strategic factor and is an essential ingredient in the development of new research perspectives.

In areas of mutual interest, the expertise and know-how of academic teams fulfil the needs of industrial partners and contribute to public and private scientific co-production. Futhermore, the access to innovative molecules is made possible thanks to these partnerships, in particular during the early phases of clinical trials.


New companies arising from research

Testifying to the dynamism of the Montpellier SIRIC team’s research, innovative biotechnology companies have been created out of its research laboratories’ findings. Fundamental discoveries made by these academic laboratories will be able to find a wide range of applications for patient care in the future.


 DiaDx-logoA.R. Thierry’s team works for more than 10 years on the investigation of cf DNA and on translational studies for evaluating the clinical potential of this novel diagnostic tool. Based upon earlier examination of the structures and origins of cfDNA, this group developped a Q-PCR based-method (Intplex), which is first multiplexed test for cfDNA.

DiaDx was created in 2015 to develop and enhance this test.

Contact: Alain Thierry

DiaDx Website


PastedGraphic-1Diag2Tec as founded in June 2015 by 5 associates (Jérôme Moreaux, Jean-Luc Veyrune, Alboukadel Kassambara, Angélique Bruyer and Pierre Vidal). Diag2Tec is an expert company devoted to hematological cancers, especially to Multiple Myeloma (MM). Main goals are to define biomarkers and generate assays to develop precision medicine approach for patients affected by these cancers.

Contact: Angélique Bruyer, Présidente

Diag2Tec Website


imageiMAb uses its proprietary phage display technology to provide pharmaceutical and biotechnology customers with antibodies with the desired characteristics for further drug development. Each project is assigned to a dedicated team, focused on a single target at a time, to configure project plans and antibody selection schemes adapted to the antigen and objectives.

iMAb works in tandem with its corresponding academic platform “GenAc” and the Inserm laboratory for a very active collaboration in research and R&D in order to continuously improve and innovate in our methods and tools.

Contact: Bernard Pau, President

iMAb Website

Metafora Biosystems

Metafora biosystems develops a unique technology based on new biomarkers nutrients transporters ligands, allowing identifying and measuring the changes in the metabolic status of living cells in normal or disrupted conditions by illness or a drug. This technology is marketed for research as METAscreen™kit. In parallel, the company leads R&D programs with industrial and academic partners to develop biomarkers for application in targeted areas (including diagnosis).

Contact: Luc d’Auriol, Président: Tél : + 33 (0)1 60 87 89 25

Metafora biosystems Website


NovaGray is developing a new generation of companion diagnostic tests aimed at improving radiation therapy planning. The overarching goal of NovaGray lies in the practitioner’s ability to tailor the dose and the sessions sequencing to the profiles of his or her patients.

This serves two purposes:

  • To tailor the patient’s medical care to his or her profile
  • To lessen side effects outbreaks

NovaGray is developing tests for breast, prostate and lung cancers.

Contact: Clémence Franc, Présidente: 06 13 99 28 98

NovaGray Website


SurgiMAb is a biotechnology company specialised in the development of injectable fluorescent conjugates. Founded by Dr Marian Gutowski, oncology surgeon at Montpellier Cancer Institute ICM and Dr André Pelegrin, Director of Montpellier Cancer Research Institute IRCM and working on the use of antibodies and their derivatives in the diagnosis and treatment of cancers, SurgiMAb develops an innovative technology that allows visualization of infra-clinical size tumors invisible to the surgeon’s naked eyes during surgery.

Contact: Francoise Cailler, Présidente: Tél : + 33 (0)4 67 61 24 17

SurgiMab Website